Pharmacological treatment of Parkinson's disease: Life beyond dopamine D2/D3 receptors?

Journal of Neural Transmission

Volumn 115, Issue 3, 2008, Pages 431-441

  Linazasoro, G ^a,c   Van Blercom, N ^a   Ugedo, L ^b   Ruiz Ortega, J A ^b  

^a Centro de Investigación de Parkinson Policlínica Guipúzcoa   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c Centro de Investigacion Parkinson   (Spain)

Author keywords

Animal models; Levodopa induced dyskinesias; Non dopaminergic drugs; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE; AMANTADINE; BACLOFEN; BUSPIRONE; CANNABINOID; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ENADOLINE; ETIRACETAM; FIPAMEZOLE; GLUTAMIC ACID; IDAZOXAN; ISTRADEFYLLINE; LEVODOPA; NORADRENALIN; OPIATE; RIMONABANT; SARIZOTAN; SEROTONIN; SPIRADOLINE; ZONISAMIDE;

DIZZINESS; DRUG EFFECT; DRUG MECHANISM; DYSKINESIA; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; MEDICAL RESEARCH; NAUSEA; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; VOMITING;

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; DOPAMINE AGENTS; HUMANS; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 40949126492     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-007-0852-z     Document Type: Review

References (93)

1. Y Agid AM Graybiel M Ruberg E Hirsch J Blin B Dubois F Javoy-Agid 1990 The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role? Adv Neurol 53 83 100
2. W Bara-Jimenez T Dimitrova A Sherzai A Favit MM Mouradian TN Chase 2004 Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease Mov Disord 19 1183 1186
3. 1A agonist in advanced Parkinson's disease Mov Disord 20 932 936
4. F Baronti MM Mouradian KE Conant 1992 Partial dopamine agonist therapy of levodopa-induced dyskinesias Neurology 42 1241 1243
5. GD Bartoszyk C van Amsterdam HE Greiner W Rautenberg H Russ CA Seyfried 2004 Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. Neurochemical profile J Neural Transm 111 113 126
6. MF Beal 2001 Experimental models of Parkinson's disease Nat Rev Neurosci 2 325 332
7. JP Bennett Jr ER Landow S Dietrich LA Schuh 1994 Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction Mov Disord 9 409 414
8. E Bezard S Ferry U Mach 2003 Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function Nat Med 9 762 777
9. F Bibbiani JD Oh TN Chase 2001 Serotonin 5HT1A agonist improves motor complications in rodent and primate parkinsonian models Neurology 57 1829 1834
10. V Bonifati E Fabrizio R Cipriani N Vanacore G Meco 1994 Buspirone in levodopa-induced dyskinesias Clin Neuropharmacol 17 73 82
11. F Bracco A Battaglia C Chouza PKDS009 Study Group 2004 The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study CNS Drugs 18 733 746
12. CA Braz V Borges HB Ferraz 2004 Effect of riluzole on dyskinesia and duration of the on state in Parkinson's disease patients: a double-blind, placebo-controlled pilot study Clin Neuropharmacol 27 25 29
13. JM Brotchie 2003 CB1 cannabinoid receptor signalling in Parkinson's disease Curr Opin Pharmacol 3 54 61
14. F Calon AH Rajput O Hornykiewicz PJ Bedard T Di Paolo 2003 Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease Neurobiol Dis 14 404 416
15. CB Carroll PG Bain L Teare 2004 Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study Neurology 63 1245 1250
16. MA Cenci IQ Whishaw T Schallert 2002 Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci 3 574 579
17. P Chaná A de Marinis N Barrientos 1997 Gabapentin and motor fluctuations in Parkinson's disease Mov Disord 12 608
18. TN Chase JD Oh 2000 Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications Ann Neurol 47 Suppl 1 S122 S130
19. KA Chung NE Carlson JG Nutt 2005 Short-term paroxetine treatment does not alter the motor response to levodopa in PD Neurology 64 1797 1798
20. MO Collins H Husi L Yu 2006 Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome J Neurochem 97 Suppl 1 16 23
21. M Doder EA Rabiner N Turjanski Aj Lees DJ Brooks 2003 Tremor in Parkinson's disease and serotoninergic dysfunction: an (11)C-WAY 100635 PET study Neurology 60 601 605
22. F Durif M Vidailhet AM Bonnet 1995 Levodopa-induced dyskinesias are improved by fluoxetine Neurology 45 1855 1858
23. F Durif B Debilly M Galitzky 2004 Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study Neurology 62 381 388
24. HH Fernandez 2006 Istradefylline for the treatment of motor response complications on levodopa in PD: results of the KW-6002-US-018 study focusing on functional and notor improvement Mov Disord 21 Suppl 15 S642
25. SH Fox B Henry MP Hill 2001 Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha-2 adrenoceptor antagonist idazoxan Mov Disord 16 642 650
26. SH Fox AE Lang JM Brotchie 2006 Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase Iia clinical studies: keys to success and roads to failure Mov Disord 21 1578 1594
27. EJ Frackiewicz SS Jhee TM Shiovitz 2002 Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa Ann Pharmacother 36 225 230
28. CG Goetz P Damier C Hicking E Laska T Müller CW Olanow O Rascol H Russ 2007 Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial Mov Disord 22 179 186
29. B Gomez-Mancilla PJ Bedard 1993 Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys Clin Neuropharmacol 16 418 427
30. M Guttman 2006 Efficacy of istradefylline in Parkinson's disease patients treated with levodopa with motor response complications: primary efficacy results of the KW-6002-US-018 study Mov Disord 21 Suppl 15 S585
31. RA Hauser 2006 Efficacy of istradefylline in levodopa-treated Parkinson's disease patients with motor response complications: secondary efficacy results of the KW-6002-US-013 study Mov Disord 21 Suppl 15 S510
32. R Hauser JP Hubble DD Truong the Istradefylline US-001 Study Group 2003 Randomized trial of the Adenosine A2A receptor antagonist istradefylline in advanced PD Neurology 61 297 303
33. B Henry SH Fox D Peggs 1999 The alpha 2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of levodopa in the MPTP-lesioned primate model of Parkinson's disease Mov Disord 14 744 753
34. B Henry SH Fox AR Crossman JM Brotchie 2001 Mu- and delta-Opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease Exp Neurol 171 139 146
35. NR Hughes AT McKnight GN Woodruff 1998 Kappa-opioid receptor agonists increase locomotor activity in the monoamine depleted rat model of parkinsonism Mov Disord 13 228 233
36. C Imbert E Bezard S Guitraud T Boraud CE Gross 2000 Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the macaque monkey J Neurosci Meth 96 71 76
37. P Jenner 2003 The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease Parkinsonism Relat D 9 131 137
38. TH Johnston JM Brotchie 2006 Drugs in development for Parkinson's disease Curr Opin Invest Drugs 7 25 32
39. T Kanda MJ Jackson LA Smith 1998 Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann Neurol 43 507 513
40. R Katzenschlager AJ Manson A Evans H Watt AJ Lees 2004 Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study J Neurol Neurosurg Psychiatry 75 295 297
41. R Klintenberg P Svenningsson L Gunne PE Andren 2002 Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism J Neural Transm 109 1295 1307
42. T Klockgether L Turski 1993 Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia Ann Neurol 34 585 593
43. AJ Lees KM Shaw G Stern 1978 Baclofen in Parkinson's disease J Neurol Neurosurg Psychiatry 41 707 708
44. G Linazasoro 2004 Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions Mov Disord 19 743 754
45. AM Lozano F Carella 2002 Physiologic studies in the human brain in movement disorders Parkinsonism Relat Disord 8 455 458
46. KE Lyons R Pahwa 2006 Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia Clin Neuropharmacol 29 148 153
47. R Mailman X Huang DE Nichols 2001 Parkinson's disease and D1 dopamine receptors Curr Opin Invest Drugs 2 1582 1591
48. AJ Manson E Iakovidou AJ Lees 2000 Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease Mov Disord 15 336 337
49. AJ Manson R Katzenschlager J Hobart 2001 High dose naltrexone for dyskinesias induced by levodopa J Neurol Neurosurg Psychiatry 70 554 556
50. NB Mercuri G Bernardi 2005 The 'magic' of l-dopa: why is it the gold standard Parkinson's disease therapy? Trends Pharmacol Sci 26 341 344
51. M Merello MI Nouzeilles A Cammarota R Leiguarda 1999 Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study Clin Neuropharmacol 22 273 276
52. D Merims I Ziv R Djaldetti 1999 Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease Lancet 353 1764 1765
53. V Mesnage JL Houeto AM Bonnet 2004 Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson's disease Clin Neuropharmacol 27 108 110
54. M Murata E Horiuchi I Kanazawa 2001 Zonisamide has beneficial effects on Parkinson's disease patients Neurosci Res 41 397 399
55. M Murata K Hasegawa I Kanazawa The Japan Zonisamide on PD Study Group 2007 Zonisamide improves motor function in Parkinson's disease. A randomized, double-blind study Neurology 68 45 50
56. NF Nichols MG Cimini JV Haas 2002 PNU-96391A (OSU6162) antagonizes the development of behavioural sensitization induced by dopamine agonists in a rat model for Parkinson's disease Neuropharmacology 43 817 824
57. CW Olanow P Damier CG Goetz 2004 Multicenter, open-label, trial of sarizotan in Parkinson's disease patients with levodopa-induced dyskinesias (the SPLENDID study) Clin Neuropharmacol 27 58 62
58. WL Olson M Gruenthal ME Mueller WH Olson 1997 Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial Am J Med 102 60 66
59. Parkinson Study Group 2000 Pramipexole vs levodopa as initial therapy for Parkinson's disease: a randomized controlled trial JAMA 284 1931 1938
60. Parkinson Study Group 2001 A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease Neurology 56 455 462
61. E Pourcher 2006 Safety and tolerability of istradefylline in Parkinson's disease with motor response complications: results of the KW-6002-US-018 study Mov Disord 21 Suppl 15 S508
62. J Qiu 2007 Debates on translational research: a balancing act Lancet Neurol 6 208 209
63. O Rascol N Fabre O Blin 1994 Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease Mov Disord 9 437 440
64. O Rascol O Blin C Thalamas 1999 ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease Ann Neurol 45 736 741
65. O Rascol DJ Brooks AD Korczyn PP De Deyn CE Clarke AE Lang 2000 A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa N Eng J Med 342 1484 1491
66. O Rascol I Arnulf PH Peyro-Saint 2001a Idazoxan, an α-2 antagonist, and L-dopa-induced dyskinesias in patients with Parkinson's disease Mov Disord 16 708 713
67. O Rascol J Nutt O Blin 2001b Induction by D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson's disease Arch Neurol 58 249 254
68. O Rascol AJ Lees W Poewe L Stalin 2006 NS2330, a dopamine reuptake inhibitor, in levodopa-treated patients with Parkinson's disease and motor fluctuations: the Phase II ADVANS study Mov Disord 21 Suppl 15 S515
69. IH Richard A Maughn R Kurlan 1999 Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series Mov Disord 14 155 157
70. PJ Richardson H Kase PG Jenner 1997 Adenosine A2a receptor antagonists as new agents for the treatment of Parkinson's disease Trends Pharmacol Sci 18 338 344
71. P Samadi L Gregoire PJ Bedard 2003 Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems Neuropharmacology 45 954 963
72. R Sandyk SR Snider 1986 Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease Am J Psychiatry 143 118
73. MC Sañudo-Pena K Tsou JM Walker 1999 Motor actions of cannabinoids in the basal ganglia output nuclei Life Sci 65 703 713
74. JM Savola M Hill M Engstrom 2003 Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease Mov Disord 18 872 883
75. AHV Schapira E Bezard J Brotchie 2006 Novel pharmacological targets for the treatment of Parkinson's disease Nature Reviews Dug Discovery 5 845 854
76. MA Schwarzschild L Agnati K Fuxe JF Chen M Morelli 2006 Targeting adenosine A2a receptors in Parkinson's disease Trends Neurosciz 29 647 654
77. A Sherzai W Bara-Jimenez A Sherzai T Dimitrova 2003 Adenosine A2A antagonist treatment of Parkinson's disease Neurology 61 293 296
78. KA Sieradzan SH Fox MP Hill 2001 Cannabinoids reduce levodopa-induced dyskinesias in Parkinson's disease: a pilot study Neurology 57 2108 2111
79. Silverdale MA, Millan MJ, Crossman AR, Brotchie JM (2002) Dopamine D3 receptor blockade, and not stimulation, is associated with anti-parkinsonian activity in the MPTP-lesioned, non-human primate model of Parkinson's disease. Soc Neurosci Abstr: S63.001
80. LC Tan PH Protell JW Langston DM Togasaki 2002 The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys Mov Disord 17 902 909
81. A Thomas D Iacono AL Luciano K Armellino A Di Iorio M Onofrj 2004 Duration of amantadine benefit on dyskinesia of severe Parkinson's disease J Neurol Neurosurg Psychiatry 75 141 143
82. JM Trugman 2006 Efficacy of istradefylline in levodopa-treated Parkinson's disease patients with motor response complications: primary efficacy results of the KW-6002-US-013 study Mov Disord 21 Suppl 15 S513
83. N Turjanski AJ Lees 1992 Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias J Neurol Neurosurg Psychiatry 55 413
84. Y Ueda T Doi J Tokumaru LJ Willmore 2003 Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures Brain Res Mol Brain Res 116 1 6
85. N Van Blercom A Lasa K Verger 2004 Effects of gabapentin on the motor response to levodopa: a double-blind, placebo-controlled, crossover study in patients with complicated Parkinson's disease Clin Neuropharmacol 27 124 128
86. L Vergahen Metman PJ Blanchet P van den Munckhof 1998a A trial of dextromethorphan in parkinsonian patients with motor response complications Mov Disord 13 414 417
87. L Vergahen Metman P Del Dotto P van den Munckhof 1998b Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease Neurology 50 1323 1326
88. L Verhagen Metman P Del Dotto K LePoole 1999 Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study Arch Neurol 56 1383 1386
89. NP Visanji J Gómez-Ramírez TH Johnston D Pires V Voon JM Brotchie SH Fox 2006 Pharmacological characterization of psychosis-like behaviour in the MPTP-lesioned nonhuman primate model of Parkinson's disease Mov Disord 21 1879 1891
90. M Williams S Wright GK Lloyd 1997 Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonists Trends Pharmacol Sci 18 307 310
91. S Yoshida M Okada G Zhu S Kaneko 2005 Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors Epilepsy Res 67 153 162
92. TA Zesiewicz KL Sullivan JL Maldonado WO Tatum RA Hauser 2005 Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease Mov Disord 20 1205 1209
93. M Ziegler V Fournier N Bathien 1987 Therapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias Clin Neuropharmacol 10 238 246